News
06-17-2013, 01:40 AM
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits...
More... (http://www.medicalnewstoday.com/releases/261928.php)
More... (http://www.medicalnewstoday.com/releases/261928.php)